MedTrace Logo

A Study of FORE8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors

NCT02428712 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 113

Last updated 2025-07-29

No results posted yet for this study

Summary

The objective of this study is to determine the safety, pharmacokinetics, maximum tolerated dose/recommended Phase 2 dose, and efficacy of FORE8394.

Conditions

  • Advanced Unresectable Solid Tumors
  • BRAF-mutated Tumors

Interventions

DRUG

FORE8394

Sponsors & Collaborators

  • Fore Biotherapeutics

    lead INDUSTRY

Principal Investigators

  • Stacie Peacock Shepherd, MD, PhD · Fore Biotherapeutics U.S. Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2024-07-12
Completion
2024-07-12

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02428712 on ClinicalTrials.gov